The Trans-Tasman Radiation Oncology Group has conducted a five year trial,
with the results published in the Lancet Oncology journal. The trial involved the Hunter Medical Research Institute, the University of
Newcastle and the Calvary Mater. More than 1,000 men were involved, with doctors using testosterone
suppression therapy, radiotherapy as well as a different type of anti-cancer
drug. The combination therapy reduced the spread of aggressive, localised tumours by
more than 40 per cent.
Denham et al., (2014). Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. The Lancet Oncology, Early Online Publication, 15 August
2014. doi:10.1016/S1470-2045(14)70328-6
You will need to contact your library to access the complete article.
No comments:
Post a Comment